Travere Therapeutics Outlook Brightens As Turnaround Looms

Biotech breakthroughs result in compelling turnaround stories, attracting stock investors well before the drug developers turn profitable. Losses during the second quarter did not deter investors from jumping into kidney drug provider Travere Therapeutics (TVTX) as they focused on its soaring sales and brightening outlook. Travere’s shares executed a breakaway gap from a flat base at a pivot of 60.10…